A Single Center, Randomized Controlled, Open Label Trial Exploring the Regulatory Effect of Telitacicept on Antibody Titers in Primary Antiphospholipid Syndrome Patients Carrying High-risk Antiphospholipid Antibody Profiles
Latest Information Update: 06 Mar 2025
At a glance
- Drugs Telitacicept (Primary)
- Indications Antiphospholipid syndrome
- Focus Therapeutic Use
- 21 Mar 2024 New trial record